Postoperative radiation therapy for patients at high‐risk of recurrence after radical prostatectomy: does timing matter?

To evaluate among radical prostatectomy (RP) patients at high‐risk of recurrence whether the timing of postoperative radiation therapy (RT) (adjuvant, early salvage with detectable post‐RP prostate‐specific antigen [PSA], or ‘late’ salvage with a PSA level of >1.0 ng/mL) is significantly associated with overall survival (OS), prostate‐cancer specific survival or metastasis‐free survival, in a longitudinal cohort.

[1]  J. Widder,et al.  Postoperative radiotherapy for prostate cancer , 2017, Strahlentherapie und Onkologie (Print).

[2]  M. Terris,et al.  Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. , 2014, European urology.

[3]  S. Goldenberg,et al.  Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. , 2013, The Journal of urology.

[4]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[5]  C. King.  The timing of salvage radiotherapy after radical prostatectomy: a systematic review. , 2012, International journal of radiation oncology, biology, physics.

[6]  M. Cooperberg,et al.  The CAPRA‐S score , 2011, Cancer.

[7]  V. Fonteyne,et al.  A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. , 2011, International journal of radiation oncology, biology, physics.

[8]  P. Mongiat-artus,et al.  [Postoperative radiotherapy of prostate cancer]. , 2010, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[9]  N. Willich,et al.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Kuban,et al.  A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. , 2008, Urology.

[11]  B. Trock,et al.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. , 2008, JAMA.

[12]  S. Hancock,et al.  Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. , 2007, International journal of radiation oncology, biology, physics.

[13]  Matthew R Cooperberg,et al.  Contemporary trends in low risk prostate cancer: risk assessment and treatment. , 2007, The Journal of urology.

[14]  D. Kuban,et al.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Parmar,et al.  RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  E. Messing,et al.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.

[17]  P. Carroll,et al.  Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. , 2006, The Journal of urology.

[18]  M. Cooperberg,et al.  The changing face of prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Kattan,et al.  Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. , 2005, The Journal of urology.

[20]  D. Kuban,et al.  Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. , 2005, International journal of radiation oncology, biology, physics.

[21]  M. Piérart,et al.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.

[22]  M. C. Parkinson,et al.  Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time , 2005, BJU international.

[23]  E. Bergstralh,et al.  The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. , 2004, The Journal of urology.

[24]  M. Hagan,et al.  Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[25]  J. Brooks,et al.  Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? , 2004, International journal of radiation oncology, biology, physics.

[26]  M. Cooperberg,et al.  The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. , 2004, The Journal of urology.

[27]  Steven Piantadosi,et al.  Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.

[28]  Douglas G Altman,et al.  Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls , 2002, The Lancet.

[29]  B. Corn,et al.  Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group. , 1999, Urology.

[30]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[31]  A. Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[32]  D. Lubeck,et al.  The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. , 1996, Urology.

[33]  M. Cooperberg,et al.  The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. , 2011 .

[34]  C. Lawton.  Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial , 2010 .

[35]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[36]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.